Aastrom to Present at 21st Annual Oppenheimer Healthcare Conference
27 October 2010 - 11:30PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of
expanded autologous cellular therapies for the treatment of severe
cardiovascular diseases, today announced that Tim Mayleben,
president and CEO, will present on behalf of the company at the
21st Annual Oppenheimer Healthcare Conference, to be held at the
Waldorf-Astoria in New York City from November 2-3, 2010.
Aastrom's presentation will take place at 12 PM ET on November
2, 2010.
The presentation will be webcast live and will be available in
the Investors section of Aastrom's website at
http://www.aastrom.com/investor.cfm. The presentation will also be
archived at the same URL for 90 days.
About Aastrom Biosciences
Aastrom Biosciences is developing expanded autologous cellular
therapies for the treatment of severe cardiovascular diseases. The
company's proprietary cell manufacturing technology enables the
production of cellular therapies expanded from a patient's own bone
marrow and delivered directly to damaged tissues. Aastrom has
advanced its cell therapies into late-stage clinical development,
including a planned Phase 3 clinical program for the treatment of
patients with critical limb ischemia and two ongoing Phase 2
clinical trials in patients with dilated cardiomyopathy. For more
information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, disease treatment and progression,
operating results, spending activities, patient symptoms and
responses to treatment, treatment options and expected timing of
collecting and analyzing treatment data, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward-looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Berry and Company
Media Contact
Stephen Zoegall
212-253-8881
szoegall@berrypr.com
Aastrom Biosciences
Investor Contact
Kimberli O'Meara
734-930-5777
ir@aastrom.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024